Diego Cadavid Email & Phone Number

Boston, MA, US

South San Francisco, CA, US

Verge is one of the few AI-driven biotech companies to have delivered on the promise of using technology to advance potential new medicines into the clinic more quickly while addressing challenging diseases with high unmet need among patients. By integrating human disease data and human model systems into the drug development process, Verge is forging a.

Worcester, MA, US

Appointed to the Faculty of the University of Massachusetts Medical School in 2018 as Affiliate Instructor of Neurology and currently practices general neurology and teaches and supervises Neurology Residents in the outpatient clinic setting.

Boston, Massachusetts, US

Responsible for the strategy, direction and execution of the company's clinical development programs.

Cambridge, Massachusetts, US

• Senior Vice President and Head of Clinical Development (2018 – 2020)Vice President and Head of Clinical Development (2016 – 2018)Member of the Executive Team reporting to the CEO. Chief Development Officer with direct.
• Managed a group of 20+ employees and contractors supporting the development function.
• Directly involved in three successful IND submissions for FSHD, SCD/beta-thalassemia, and COVID-19.
• Established SOPs for the clinical development organization and set up GDPR compliance and training program.
• Created and managed clinical advisory boards for FXS, FSHD, SCD, and COVID-19 programs.
• Supported multiple successful regulatory interactions, including pre-IND and type C meetings and a CPIM.

Cambridge, MA, US

• Medical director for the CNS Remyelination Group, leading two first in class molecules into the clinic, one small molecule and one biologic including two phase 1 and two phase 2 studies.
• Served as the team medical leader for the progressive MS group including a Phase Ib study, a partner Phase II study, and a global registrational Phase III study.
• Served as development medical lead on the PML mitigation activities for Tysabri in MS.
• Participated in regulatory interactions in the US and Europe, including IND filings, End of Phase II meetings, successful negotiation of SPA agreement with FDA, EMA meetings, and individual EU member meetings.
• Supported payor interactions in North America (US and Canada) and Europe (UK and Germany).
• Organized and served as lead on advisory boards in the US, Canada, and Europe with key opinion leaders, technical experts, and regulatory and payor advisors.

Cambridge, MA, US

Cambridge, MA, US

Boston, MA, US

NIH funded research on injury and protection of the blood brain barrier during borrelial infections

Newark, NJ, US

• Associate Professor of Neurology and Neuroscience, on Tenure Track (2004 – 2008) Assistant Professor of Neurology and Neuroscience (1999 – 2004)Responsible for basic and clinical research, teaching, inpatient and.
• Principal Investigator in two R21 NIH grant awards, one American Heart Association Scientist Development Grant, and a $4M industry grant for a MS comparative efficacy trial. Head of the laboratory of borrelia.
• Performed clinical care activities at the MS clinics of Rutgers-New Jersey Medical School and Holy Name Hospital in Teaneck, and inpatient clinical care at University Hospital-Newark.
• Served as Vice Chair of the Animal Care Committee and as member of the Student Affairs Committee.
• Member of the Center for the Study of Emerging Pathogens and Hispanic Center of Excellence.

Adult Neurologists, Neurology

Fellowship, Neuropathology

Postdoctoral Fellowship, Microbiology And Immunology, Internal Medicine

Md, Medicine